Dyslipidaemia and its treatment in patients with type 2 diabetes: A joint analysis of the German DIVE and DPV registries.
To compare lipid abnormalities in people with and without type 2 diabetes mellitus (T2DM) and to assess the effect of treatment.



We combined data from the German DIVE (DIabetes Versorgungs-Evaluation) and DPV (Diabetes-Patienten-Verlaufsdokumentation) databases to produce a large cohort of people with T2DM. The characteristics of people receiving and not receiving lipid-modifying therapy (LMT) were compared, including demographics, cardiovascular (CV) risk factors and comorbidities. Lipid profiles were evaluated, and the achievement of recommended LDL cholesterol and non-HDL cholesterol targets was assessed. The effect on lipid levels in subgroups of patients aged ≥60 years, being obese or with CV disease was also investigated.



A total of 363 949 people were included in the analysis. Of these, only 97 160 (26.7%) were receiving LMT. These individuals were older than those not receiving LMT, and comorbidities were more prevalent. Statins were the most commonly used agents (84.2%), with ezetimibe, fibrates and nicotinic acid taken by a small proportion of people. The median LDL cholesterol level was lower for the LMT group (100.5 vs 114.0 mg/dL; P < .001), as was the non-HDL cholesterol level (131.0 vs 143.1 mg/dL; P < .001), while the triglyceride level was higher (160.3 vs 152.0 mg/dL; P < .001). HDL cholesterol was lower in the LMT group for both men (41.0 vs 42.0 mg/dL; P < .001) and women (47.5 vs 48.0 mg/dL; P < .001). Elderly people were more likely to have achieved the target lipid levels, while obese people were less likely. For people with CV disease, there was a greater likelihood of achieving LDL, total and non-HDL cholesterol targets, but less chance of attaining a desired HDL cholesterol level.



Dyslipidaemia was highly prevalent in this large population and management of lipid abnormalities was suboptimal. The distinct lipid profile of people with T2DM warrants further investigation into the use of non-statins in addition to statin LMT.
Institute for Pharmacology and Preventative Medicine, Mahlow, Germany. peter.bramlage@ippmed.de.
Peter
P
Bramlage
ZIBMT, Institute of Epidemiology and Medical Biometry, University of Ulm, Ulm, Germany.|Deutsches Diabetes Zentrum, München-Neuherberg, Germany.
Stefanie
S
Lanzinger
Institute of Biometry and Epidemiology, Deutsches Diabetes Zentrum, Düsseldorf, Germany.
Wolfgang
W
Rathmann
Herz-Jesu-Krankenhaus Münster, Münster, Germany.
Anton
A
Gillessen
Diabetesschwerpunktpraxis, Marl, Germany.
Nikolaus
N
Scheper
Medizinische Klinik 1, Universitätsklinikum Schleswig-Holstein, Lübeck, Germany.|Deutsches Diabetes Zentrum, Lübeck, Germany.
Sebastian M
SM
Schmid
Diabetesschwerpunktpraxis, Leverkusen, Germany.
Matthias
M
Kaltheuner
Department of Internal Medicine, Universitätsklinikum Freiburg, Freiburg, Germany.
Jochen
J
Seufert
Diabeteszentrum für Kinder und Jugendliche, Kinderkrankenhaus auf der Bult, Hannover, Germany.
Thomas
T
Danne
ZIBMT, Institute of Epidemiology and Medical Biometry, University of Ulm, Ulm, Germany.|Deutsches Diabetes Zentrum, München-Neuherberg, Germany.
Reinhard W
RW
Holl
age; cardiovascular; cholesterol; diabetes; lipids; obesity; statins; triglycerides